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Available online 29 June 2016Phosphoﬂow cytometry is increasingly being used as a tool for the discovery of biomarkers used in the treatment
andmonitoring of disease and therapy. The ability tomeasure numerous phospho-protein targets simultaneous-
ly at a single cell level accurately and rapidly provides signiﬁcant advantages over other methods. We here dis-
cuss important considerations required to successfully implement these methods. Three different blood
collection tubes (lithium-heparin tubes, CPT with sodium citrate and CPT with sodium heparin) were evaluated,
with PBMC isolated through lithium-heparin tubes/lymphoprep displaying reduced basal and increased stimula-
tion induced phosphorylation compared to the other twomethods. Further, we provide a protocol outlining an 8
color assay developed for the study of intracellular signaling in peripheral bloodmononuclear cells. The assay al-
lows for the quantitative measurement of the phospho-proteins ERK1/2, NF-κB p65, Stat1 (Y701), Stat1 (S727),
Stat3 (Y705), Stat3 (S727), Stat4 (Y693), p38 and Stat5 (Y694), as well as the identiﬁcation of T cells, B cells, nat-
ural killer cells and monocytes. The assay additionally incorporates ﬂuorescent cell barcoding, reducing assay
costs and increasing throughput while increasing data robustness. Inter-assay precision was assessed over a
month long period for all experimental variables (phospho-protein measured, cell type and stimulant). Coefﬁ-
cient of variations (CVs) calculated from process triplicates of normalized median ﬂuorescence intensity (MFI)
of the phospho-proteins displayed median CVs under 10% when grouped according to cell type, stimulation
agent and phospho-protein measured, while the CV for each triplicate did not exceed 20%.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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By using highly speciﬁc ﬂuorochrome conjugated antibodies, ﬂow
cytometry allows for quantitative multi-parameter analysis of single
cells within complex cell populations. The additional use of ﬂuoro-
chrome conjugated antibodies to the phosphorylated forms of mole-
cules phosphorylated during signaling cascades allows for the analysis
of signalingnetworkswithin complex cell populations such as peripher-
al blood mononuclear cells (PBMCs). This provides quantitative data of
phosphorylation events at a single cell level; without the need for prior
separation of the cells of interest (Krutzik and Nolan, 2003). The path-
way of interest can be further investigated through its activation eitheroratory, Department of Clinical
5th ﬂoor, Jonas Lies vei 87, N-
ansfusion Medicine, Haukeland
. This is an open access article underin vivo or in vitro. This technique termed phospho-ﬂow cytometry has
shown signiﬁcant promise in stratiﬁcation of disease (Irish et al., 2004,
Brown et al., 2015), monitoring disease progression (Cesano et al.,
2013) and identiﬁcation of biomarkers for monitoring therapeutic in-
tervention (Gavasso et al., 2014). Additionally the method can be used
in conjunction with ﬂuorescent cell barcoding to enable a higher
throughput while minimizing reagent consumption and maximizing
data robustness through the multiplexing of samples prior to staining;
making this method ideal for proﬁling of multiple samples (Krutzik
et al., 2011).
We here provide a protocol outlining an 8 color assay developed for
the study of intracellular signaling in PBMCs. In the procedure, PBMCs
are stimulated, ﬁxed, permeabilized and stained with 3 different anti-
body panels to identify various cell types - T cells, B cells and natural kill-
er (NK) cells, and phospho-proteins-NF-κB p65 (pS529), ERK 1/2
(pT202/pY204), P38 (pT180/pY182), Stat4 (pY693), Stat1 (pY701),
Stat1 (pS727), Stat3 (pY705), Stat5 (pY694) and Stat3 (pS727). Addi-
tionally, we utilize 2 amine reactive dyes, Paciﬁc Orange™ (PO) and Pa-
ciﬁc Blue™ (PB) to barcode 9 different samples, allowing for a higherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cuss important issues related to the testing and development of in-
house assays such as the choice of the blood collection tube.
2. Materials and methods
A schematic representation of the work ﬂow and gating strategy is
shown in Fig. 1.
2.1. Antibodies
The following phospho-speciﬁc monoclonal antibodies were used in
3 different panels during theﬂow cytometry protocol: Alexa Fluor ®647
conjugated anti-Stat4 (pY693, clone 38/p-Stat4, panel 1), anti-Stat 1
(pS727, clone K51-856, panel 2) and anti-Stat3 (pS727, clone 49/p-
Stat3, panel 3); PerCP-Cy™5.5 conjugated anti-ERK1/2 (pT202/pY204,
clone 20A, panel 1), anti-Stat1 (pY701, clone 4a, panel 2) and anti-
Stat3 (pY705, clone 4/P-STAT3, panel 3); and PE-Cy™7 conjugated
anti-p38 MAPK (pT180/pY182, clone 36/p38, panel 2), and anti NF-κB
p65 (pS529, clone K10-895.12.50, panel 1), anti-Stat5 (pY694, clone
47/Stat5(pY694), panel 3) (all from BD Biosciences, San Jose, CA, USA).
Cell surface markers incorporated in the assays were BV786 conjugated
anti-CD3 (clone SK7, BD Horizon™), Alexa Fluor® 488 conjugated anti-
CD20 (clone H1 (FB1), BD Biosciences) and PE conjugated anti-CD56
(clone N901, Beckmann Coulter, CA, USA).Fig. 1. Schematic representation of the work ﬂow and gating strategy used in the analysis of int
diagnostics), and PBMCs were isolated by density gradient centrifugation before cryopreservat
divided into 9 wells and stimulated as described in materials and methods. After stimulation, sa
(PB) andpaciﬁc orange (PO) dyes. Sampleswerewashed to remove excess dye and combined in
methods. Sampleswere analyzedonaﬂowcytometer, single cellswere gatedbased on their forw
on side scatter area (SSC-A) and FSC-A. The different stimulation conditions were then identiﬁe
their FSC-A and SSC-A scatter properties as either monocytes or lymphocytes. Lymphocytes we
CD3+CD56+ NKT cells based on surface antigen expression. Cells within each subtype w
unstimulated reference sample. Data was analyzed, scatter graphs and heat maps were produc2.2. Blood collection
Blood was collected at the blood bank at the Haukeland University
Hospital in Bergen, Norway. All blood donors provided written in-
formed consent. Peripheral blood was collected in Lithium-heparin
tubes (BD diagnostics) and peripheral blood mononuclear cells
(PBMCs) were isolated by density gradient centrifugation with
lymphoprep™ (Axis-Shield, Oslo, Norway) as permanufactures instruc-
tions. For the experiments analyzing the effect of the isolation method,
BD Vacutainer® CPT™ with Sodium Citrate or Sodium Heparin (BD di-
agnostics) were utilized. PBMCs were washed twice with phosphate
buffered saline (PBS; Lonza, Basel, Switzerland) before being resus-
pended in ice cold 50%X-vivo 20™ and 42.5% Profreeze™-CDMnon-an-
imal origin (NAO) chemically deﬁned freezemedium (both from Lonza)
and 7.5% DMSO (Hybrid max, Sigma D2650) at 3 to 5 × 106 cells/ml.
PBMCs were then frozen in a CoolCell® (Biocision; San Rafael, CA,
USA) freezing chamber at−70 °C overnight before being moved to a
−150 °C freezer for approximately 6 months.
2.3. Cell culture and stimulation
Before stimulation, cryopreserved PBMCs were rapidly thawed
using a water bath set to 37 °C and washed once in prewarmed X-vivo
20™ by centrifugation at 300g for 5min. The cells were then resuspend-
ed in X-vivo 20™ and rested at 37 °C at 5% CO2 for 30min before the cellracellular signaling pathways in PBMCs. Blood was collected in Lithium-heparin tubes (BD
ion. At a later date PBMCs samples were thawed and rested in serum free media and then
mples were ﬁxed, permeabilized and stained with different concentrations of paciﬁc blue
to one tube and stainedwithﬂuorochrome conjugated antibodies as given inMaterials and
ard scatter area (FSC-A) and forward scatterwidth (FSC-W), followedby intact cells based
d through the intensities of their PB and PO stains. Cell subtypes were identiﬁed based on
re then subtyped as B cells (CD20+), T cells (CD3+CD56−), NK cells (CD3−CD56+) or
ere analyzed based on the change of MFI in each stimulation condition relative to the
ed in cytobank (Kotecha et al., 2010).
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400 μl was dispensed into 9 wells of a Megablock® 96 well plate
(Starstedt, Nümbrecht, Germany). The cells were rested at 37 °C with
5% CO2 for 11/2 h to decrease basal phosphorylation levels. Following,
the PBMCs were either left unstimulated (2 samples) or were stimulat-
ed for 15 min with cytokines (100 ng/ml), LPS (10 μg/ml; Sigma-Al-
drich) or PMA (100 ng/ml; Sigma-Aldrich) at 37 °C with 5% CO2.
Recombinant human (rh) interleukin-10 CHO (IL-10), interleukin-2
(IL-2), interleukin-6 (IL-6), interferon-alpha 2 beta (IFNα2β), IFN-
gamma (IFNγ) were from ImmunoTools (Friesoythe, Germany). Lyoph-
ilized cytokines and LPS were reconstituted in X-vivo 20™, while PMA
was reconstituted in DMSO. All compounds were diluted in 100 μl X-
vivo 20™ and added to 400 μl of cells resulting in a ﬁnal cell concentra-
tion of 1 × 106 cells/ml during stimulation. All assayswere performed in
serum free media (X vivo-20™) to allow for a constant stimulation en-
vironment for the PBMCs and avoid unspeciﬁc stimulation.
2.4. Fluorescent cell barcoding and phospho-epitope staining for ﬂow
cytometry
PBMCswere ﬁxed by adding 16% PFA (ElectronMicroscopy Sciences
(Hatﬁeld, PA, USA) warmed to 37 °C directly into the culture medium
resulting in a ﬁnal PFA concentration of 1.5%. The samples were mixed
thoroughly by pipetting. The cells were ﬁxed at RT for 10 min before
pelleting at 1000 g for 5 min. The PBMCs were then vigorously resus-
pended by vortexing in 50 μl PBS before drop wise addition of 1 ml ice
cold methanol and incubation on ice for 30 min. The permeabilized
cells were kept overnight at −80 °C. After washing with PBS, the
PBMCs were stained according to a 3 × 3 barcoding grid (9 stimulation
conditions) using 3 levels of paciﬁc orange (PO) and paciﬁc blue (PB)
succinimidyl ester dyes (PB 100, 25 and 6.3 ng/ml; PO 250, 70 and
0 ng/ml; Life Technologies, Grand Island, NY, USA) for 30 min in the
dark at 4 °C in a volume of 1 ml. Barcoded PBMCs were then washed
once and the 9 different dye concentration/combination samples were
combined into one sample. The sample was washed and incubated
with 1 μl Fc receptor block (Miltenyi Biotec, Bergisch Gladbach, Germa-
ny) per 1 × 106 cells for 10 min on ice. Following, the sample was
subdivided into 3 volumes and incubated for 30 min at RT in the dark
with the 3 different antibody staining panels. An aliquot of the barcoded
cells was collected before addition of antibody as a barcoding only con-
trol. The samples were thenwashed twice and re-suspended in staining
medium containing 2 mM EDTA (Sigma-Aldrich) prior to analysis.
2.5. Analysis
Samples were acquired on a LSRI Fortessa ﬂow cytometer (BD Bio-
sciences, San Jose, CA, USA) with BDFACSDiVa™ Software (BD Biosci-
ences) at the Bergen Flow Cytometry Core Facility, University of
Bergen, Norway. The ﬂow cytometer was equipped with 407, 488, 561
and 635 nm lasers, and emission ﬁlters for PerCP-Cy5.5 (LP: 685, BP:
695/40), Alexa ﬂuor-488 (LP: 505, BP: 530/30), PE-Cy7 (LP: 750, BP:
780/60), PE (LP:−, BP: 582/15), APC (LP:−, BP: 670/14), Paciﬁc blue
(LP: −, BP:450/50), Paciﬁc orange (LP: 570, BP: 585/42) and BV 786
(LP: 750, BP: 780/60). The cytometer was routinely calibrated with BD
cytometer setup and tracking beads (BD Biosciences). A minimum of
200,000 events in the intact cell gatewas collected for each sample. Gat-
ingwas conducted as shown in Fig. 1: First, single cellswere gated based
on forward scatter area (FSC-A) and forward scatter width (FSC-W)
properties, followed by intact cells based on side scatter area (SSC-A)
and FSC-A. The different stimulation conditions were then identiﬁed
through the intensities of their PB and PO stains against SSC-A. Cell sub-
types were identiﬁed based on their FSC-A and SSC-A scatter properties
as either monocytes or lymphocytes. Lymphocytes were further
subtyped as B cells (CD20+), T cells (CD3+CD56−), NK cells
(CD3−CD56+) or CD3+CD56+ NKT cells based on surface antigen
expression. The fold change (arcsinh) was calculated from medianﬂuorescence intensity values (MFI) of unstimulated controls to MFI of
each stimulated samples for each identiﬁed PBMC subtype. Fold change
(arcsinh) was calculated through Cytobank or alternatively through
Microsoft Excel using the formula (ASINH (MFI stimulated/cofactor)) -
(ASINH (MFI unstimulated/cofactor)), with an assigned cofactor of
150. To assess the precision of the multiplexed assay complete process
triplicateswere run using cryopreserved PBMCs from3 different donors
over a 1month period. MFI values of target phospho-proteinswere nor-
malized against their respective unstimulated samples and coefﬁcient
of variation (CV) values were calculated based on the normalized tripli-
cate values. Additionally we cryopreserved PBMCs from a single donor
with unstimulated and stimulated samples run in each assay for a pos-
itive control, inter-assay normalization, assessing assay to assay vari-
ability and calculating relative basal phosphorylation level in the
unstimulated sample.
3. Results
3.1. The PBMC isolation method affects their signaling proﬁle in a cell and
pathway dependent manner
We ﬁrst compared the effect of different PBMC isolation methods.
The signaling proﬁle of PBMCs separated using CPT sodiumcitrate or so-
dium heparin tubes as well as collection with lithium-heparin tubes
followed by density gradient separation of PBMCs are shown in Fig. 2.
The ﬁgure shows fold changes (arcsinh) for monocytes, T cells
(CD3+), NK cells (CD3−CD56+), CD3+CD56+ NKT cells and B
cells CD20+) measured in channels for pERK, pNF-κB, pP38, pStat1
S727, pStat1 Y701, pStat3 S727 pStat3 Y705, pStat4 Y693 and pStat5
Y694.Measurementsweremade for all 3 donor PBMCs and fold changes
were calculated by comparing unstimulated samples to their respective
stimulated samples for each donor and basalmeasurementswere calcu-
lated against an unstimulated single donor control. The signaling proﬁle
was affected in a cell and pathway dependent manner. Differences
among the groups were assessed through repeated measures one-way
ANOVA, with the Greenhouse-Geisser correction and Holm-Sidak's
multiple comparisons test, p ˃ 0.05 was considered signiﬁcant. Basal
measurements of cells derived from different PBMC isolation methods
differed signiﬁcantly. Lithium-heparin tubes followed by density gradi-
ent separation of PBMCs showed signiﬁcantly lower basal phosphoryla-
tion of Erk1/2, P38, Stat1 Y701, Stat3 S727 and Stat5 Y694 in multiple
cell types than those isolated through CPT sodium citrate or sodium
heparin tubes. PBMC samples showed signiﬁcant differences in fold
changes following stimulation between PBMC isolation methods. Fold
changes of PBMCs isolated using tubes with heparin additives were
comparable, but differed signiﬁcantly from the citrate tube. In particular
a decreased phosphorylation fold change for NF-κB, Stat1 Y701, Stat3
Y705 and Stat5 Y694 following stimulation when compared to their re-
spective unstimulated controls was exhibited. These differences were
shown in multiple cell types but were most notable in NK cells, where
for example pStat4 had mean fold change of 1.29 when peripheral
blood was collected in lithium-heparin tubes compared to 0.337 with
CPT tubes with sodium citrate. These decreases were often not corre-
sponding with increases in basal signaling (e.g. Stat4 Y693 and Stat3
S727 in NK cells) and therefore do not explain the observed repression
3.2. Phosphoﬂow distinguishes cell and treatment speciﬁc signaling proﬁles
Examples of results from following the described method is shown
as a heat map in Fig. 3A. The ﬁgure displays a scale indicating fold
change (arcsinh) relative to their respective unstimulated sample. Dif-
ferent cell subsets in PBMCs are activated to different degrees depen-
dent on the agent used in cell stimulation. Interferon α was shown to
activate multiple phospho-proteins, this was strongly shown in pStat4
and pStat1 (Y701) and to lesser degrees pStat3 (Y705), pStat3 (S727)
and pStat5, with the level of activation dependent on cell type. While
Fig. 2. Effect of PBMC isolation method on cell signaling. The Isolation method is displayed at the base of the ﬁgure with lithium-heparin (LH) tubes, CPT with sodium-citrate (CPT-C) or
sodium-heparin (CPT-H) shown. Cell type is shown on top and phospho-protein measured on the right of the ﬁgure. The axis for phosphorylation fold change (arcsinh) following
stimulation and basal fold differences (arcsinh) are shown on the left hand side of the ﬁgure. Basal fold differences are shown on the left hand side of the ﬁgure (A) and are
represented by grey bars while fold changes following stimulation are shown on the right (B). The bars show the mean and standard deviation. The PBMC isolation method was
shown to have an effect on degree of signaling in PBMCs after stimulation with PMA and interferon α for 15 min and basal levels. These effects varied with cell type and kinase
measured. In most cases peripheral blood mononuclear cells isolated using CPT (CPT-H and CPT-C) showed higher degrees of basal phosphorylation then PBMCs isolated by lithium-
heparin tubes and density gradient centrifugation. Heparin based isolation methods resulted in stronger post stimulation fold changes. A repeated measure one-way ANOVA, with the
Greenhouse-Geisser correction and Holm-Sidak's multiple comparisons test was used to analyze differences between groups, signiﬁcant p values are denoted as * ≤ 0.05, ** ≤ 0.01,
*** ≤ 0.001, **** ≤ 0.0001.
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Fig. 3. Phosphoﬂow distinguishes cell and treatment speciﬁc signaling proﬁles. A. Heat map representation of the stimulation proﬁle of PBMCs. Data was generated as outlined in the
protocol with antibody panels used in the analysis shown to the right of the maps. All cells were gated according to the schematic shown in Fig. 1. The columns represent the cell
subsets, T cells, B cells, NK cells, CD3+CD56+ cells and monocytes. Each row represents a sample stimulated with a cytokine or chemical, with the phospho-speciﬁc antibody
detected shown at the base of each map. The color of each block represents the fold change (arcsinh) in the channel corresponding to the analyzed phosphorylated protein relative to
the un-stimulated sample, and the degree of change shown in the scale at the ﬁgure base. Data was analyzed and heat maps produced in cytobank (Kotecha et al., 2010). B. Precision
of ﬂow cytometry based phospho-protein measurements of PBMCs from 3 different donors. Analysis of PBMCs shows excellent precision of normalized MFI values of phospho-
proteins. CV values for the multiplexed assays measured in complete process triplicates, grouped according to cell type analyzed (upper panel. n = 189), stimulation agent (medium
panel. n= 135) and phospho-protein measured (lower panel. n= 105). Upper panel: The cell speciﬁc group median assay CVs were 4.76% (monocytes), 2.88% (CD3+ T cells), 3.64%
(CD56+ NK cells), 4.61% (CD3+CD56+ cells) and 4.73% (CD20+ B cells), with 95% of the results having CVs within 10% (CD3+ T cells and CD56+ NK cells) and 13% (monocytes,
CD3+CD56+ cells and CD20+ B cells). Medium panel: CV values grouped by stimulation agent showed medians of 3.84% (IFNα), 4.27% (IFNγ), 3.8% (IL-10), 2.88% (IL-2), 3.64% (IL-
6), 5.62% (LPS) and 4.96% (PMA), with 95% of the results having CVs within 10% (IFNα and IL-6), 12% (IFNγ, IL-10, IL-2 and PMA), and 15% (LPS). Lower panel: CV values grouped by
phospho-protein measured had median assay CVs of 3.36% (pERK 1/2), 4.62% (pNfκB), 5.81% (pStat4), 3.56% (pStat1(Y701)), 5.05% (pStat1(S727)), 3.98% (pP38), 3.16%
(pStat3(Y705)), 2.80% (pStat3(S727)) and 4.79% (pStat5), with 95% of the results having CVs within 10% (pERK 1/2, pNfκB, pStat1(Y701), pStat3(Y701), pStat3(S727)) and 15%
(pStat4, pStat1(S727), pP38, pStat5). Box plots show the medium value plotted as a line with each box displaying the distribution of the inner quartiles and vertical lines showing 95%
of the data.
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activation was limited to pStat1 (Y701), pStat1 (S727), pStat3 (Y705),
pStat3 (S727) and pStat5 in monocytes; as well as pStat1 (Y701) in B
cells. Interleukin-10 showed a greater degree of speciﬁcity in
phospho-protein activation, strong induction was shown in pStat3
(Y705) in all cell types with relatively lower levels of activation of
pStat3 (S727). Interleukin-2 activation was largely limited to activation
of pStat5 in T cells, NK cells and CD3+CD56+NKT cells. IL-6 activation
was more pronounced in T cells in particular pStat1 (Y701), pStat3
(Y705) and pStat3 (S727); while LPS displayed a higher levels of activa-
tion in monocytes of NF-κB and P38. PMA showed high phospho-pro-
tein activation in diverse cell types, with strong activation of ERK 1/2,
NF-κB, P38 and Stat3 (S727).
3.3. Multiplex assay shows good reproducibility over phosphor-proteins,
cell types and stimulations
To assess the precision of the established assay; PBMCs from 3 sepa-
rate donors were isolated and cryopreserved. Subsequently on 3separate occasions over a 1 month period, PBMCs for each donor were
thawed and processed as described in the method. Data of measured
MFI for each phospho-protein under each stimulation conditionwas nor-
malized against the corresponding unstimulated controls for each
phospho-protein, cell type and donor. The coefﬁcient of variation (CV;
100 ∗ standard deviation/mean) was calculated for the 3 replicates for
each normalized phospho-protein MFI measurement in each cell type
and stimulation agent. The results generated were grouped for each
phospho-protein, cell type and stimulation agent and are shown in Fig.
3B. The data indicates excellent precision ofmeasurements; with robust-
ness of the assay also shown to be dependent on cell type and phospho-
protein measured, as well as stimulation agent. The assay was shown to
be more precise in measurements of pERK 1/2, pNF-κB, pStat1 (Y701),
pStat3 (Y705) and pStat3 (S727) than pStat4, pStat1 (S727), pP38 and
pStat5 with median CVs of 3.36%, 4.62%, 5.81%, 3.56%, 5.05%, 3.98%,
3.16%, 2.80% and 4.79%, respectively, with 95% of the results having CVs
within 10% (pERK 1/2, pNF-κB, pStat1(Y701), pStat3(Y701),
pStat3(S727)) and 15% (pStat4, pStat1(S727), pP38, pStat5). CVs for
the triplicate phospho-protein measurements of T cells (2.88%) and NK
63R. Davies et al. / Journal of Immunological Methods 436 (2016) 58–63cells (3.64%) were lower than those of monocytes (4.76%),
CD3+CD56+ cells (4.61%) and B cells (4.73%). 95% of the results had
CVswithin 10% for CD3+T cells and CD56+NK cells and13% formono-
cytes, CD3+CD56+ cells and CD20+ B cells. Additionally, assay preci-
sion was shown to be greater using cytokine based stimulation
(median CVs of 3.84% (IFNα), 4.27% (IFNγ), 3.8% (IL-10), 2.88% (IL-2),
and 3.64% (IL-6)) than LPS (5.62%) or PMA (4.94%). Still, 95% of the re-
sults had CVs below 10% (IFNα and IL-6), 12% (IFNγ, IL-10, IL-2 and
PMA) and 15% (LPS).
4. Discussion and conclusion
The monitoring of phosphorylation in signal transduction pathways
is increasingly being seen as a relevant tool in the treatment of disease
with multiple research groups showing its promise in the monitoring
(Huang et al., 2011) and prognosis (Brown et al., 2015) of disease, as
well predicting and monitoring therapeutic treatments (Everson et al.,
2014, Gavasso et al., 2014). Phosphoﬂow cytometry which can quanti-
tate the level of phosphorylation in numerous phospho-protein targets
simultaneously at a cell type-speciﬁc, single cell level provides an ideal
tool for these research endeavors. Accurate measures require well test-
ed and validated panels showing consistent and reproducible results.
Here we presented 3 panels for an optimized 8 color multiplexed
phosphoﬂow assays for the analysis of cryopreserved PBMC samples.
The assays incorporates monoclonal antibodies speciﬁc for phospho-
proteins ERK 1/2, NF-κB p65, Stat1 (Y701), Stat1 (S727), Stat3 (Y705),
Stat3 (S727), Stat4, Stat1 (S727), P38 and Stat5. These targets were cho-
sen as their activation is involved in numerous immune responses.
Moreover, associations have been shownwith dysregulation of intracel-
lular signaling molecules involved in immune responses and autoim-
munity (O'Shea and Plenge, 2012). The assay incorporates markers for
common cell lineages in peripheral blood - T cells, B cells and NK cells;
while monocytes were identiﬁed using their scatter properties. Addi-
tionally the assays utilize a 9× barcoding matrix allowing up to 9 sam-
ples to be measured simultaneously as 1 sample. This signiﬁcantly
reduces antibody consumption and ﬂow cytometry acquisition times,
signiﬁcantly reducing the cost and time required to process and mea-
sure multiple samples, while additionally increasing data robustness.
The use of heparin as an anti-coagulant was shown to be superior in
retaining PBMC responsiveness compared to citrate. Citrate strongly af-
fected NK cell responses to stimuli in multiple kinases, while CPT based
isolation methods were associated with higher basal phosphorylation.
Because of the varied response in PBMC subtypes we recommend
prior testing before committing on blood collection methodology. Care
should be taken to assess the isolation procedures effect on responses
by different cell type. Additionally the resting period prior to PBMC
stimulation should be optimized with regards to isolation protocol
used to minimize basal signaling. As an example to illustrate thestrength of this method we measured multiple phospho-proteins
under multiple stimulation conditions simultaneously within a single
barcoded sample in triplicates for 3 different donors. The assay showed
excellent inter-assayprecision over amonth long periodwith CVs calcu-
lated against process triplicates of normalized MFI of the phospho-pro-
teins displaying median CVs of under 10% when grouped by cell type,
stimulation agent and phospho-proteinmeasured, while the CV derived
from each normalized triplicate measurement did not exceed 20%.
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